$ADVM
Adverum Biotechnologies, Inc.

2022 Q4 Form 10-Q Financial Statement

#000162828022029499 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.641M $17.19M $13.35M
YoY Change -18.95% 28.72% 17.65%
% of Gross Profit
Research & Development $22.20M $23.85M $24.07M
YoY Change -1.44% -0.91% 44.53%
% of Gross Profit
Depreciation & Amortization $1.712M $1.788M $962.0K
YoY Change 29.5% 85.86% -18.47%
% of Gross Profit
Operating Expenses $31.84M $41.04M $38.52M
YoY Change -7.49% 6.53% 37.56%
Operating Profit -$41.04M -$38.52M
YoY Change 6.53% 37.56%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $1.223M $923.0K $160.0K
YoY Change 12130.0% 476.88% -31.91%
Pretax Income -$32.72M -$40.11M -$38.36M
YoY Change -4.92% 4.57% 38.14%
Income Tax $19.00K $17.00K $0.00
% Of Pretax Income
Net Earnings -$32.74M -$40.13M -$38.36M
YoY Change -4.86% 4.61% 38.15%
Net Earnings / Revenue
Basic Earnings Per Share -$0.40 -$0.39
Diluted Earnings Per Share -$0.33 -$0.40 -$0.39
COMMON SHARES
Basic Shares Outstanding 99.73M shares 99.33M shares 98.13M shares
Diluted Shares Outstanding 99.48M shares 98.13M shares

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $185.6M $203.3M $332.7M
YoY Change -39.19% -38.91% -26.8%
Cash & Equivalents $68.43M $84.43M $32.97M
Short-Term Investments $117.2M $118.8M $299.7M
Other Short-Term Assets $5.006M $9.979M $7.764M
YoY Change -19.88% 28.53% 49.31%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $190.6M $213.2M $347.8M
YoY Change -39.9% -38.69% -24.34%
LONG-TERM ASSETS
Property, Plant & Equipment $34.93M $36.58M $37.16M
YoY Change 5.65% -1.56% 36.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.413M $155.0K $138.0K
YoY Change 465.2% 12.32% 626.32%
Total Long-Term Assets $117.8M $119.1M $142.8M
YoY Change -3.92% -16.56% 197.34%
TOTAL ASSETS
Total Short-Term Assets $190.6M $213.2M $347.8M
Total Long-Term Assets $117.8M $119.1M $142.8M
Total Assets $308.4M $332.4M $490.6M
YoY Change -29.87% -32.25% -3.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.238M $846.0K $2.517M
YoY Change 61.36% -66.39% -17.04%
Accrued Expenses $29.75M $27.47M $21.56M
YoY Change 59.84% 27.43% 64.58%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $32.25M $28.62M $25.33M
YoY Change 51.25% 13.01% 57.2%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.047M $940.0K $1.114M
YoY Change -6.01% -15.62% 719.12%
Total Long-Term Liabilities $1.047M $940.0K $1.114M
YoY Change -6.01% -15.62% 719.12%
TOTAL LIABILITIES
Total Short-Term Liabilities $32.25M $28.62M $25.33M
Total Long-Term Liabilities $1.047M $940.0K $1.114M
Total Liabilities $126.9M $124.0M $144.6M
YoY Change 2.68% -14.22% 236.24%
SHAREHOLDERS EQUITY
Retained Earnings -$802.6M -$769.9M -$613.7M
YoY Change 23.84% 25.45% 32.01%
Common Stock $985.7M $980.2M $960.2M
YoY Change 2.14% 2.08% 3.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $181.5M $208.3M $346.0M
YoY Change
Total Liabilities & Shareholders Equity $308.4M $332.4M $490.6M
YoY Change -29.87% -32.25% -3.37%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$32.74M -$40.13M -$38.36M
YoY Change -4.86% 4.61% 38.15%
Depreciation, Depletion And Amortization $1.712M $1.788M $962.0K
YoY Change 29.5% 85.86% -18.47%
Cash From Operating Activities -$18.47M -$31.81M -$25.80M
YoY Change -28.43% 23.31% -2.84%
INVESTING ACTIVITIES
Capital Expenditures $185.0K -$824.0K -$5.719M
YoY Change -104.25% -85.59% 85.68%
Acquisitions
YoY Change
Other Investing Activities $2.419M $25.19M $16.19M
YoY Change -91.43% 55.61% -112.52%
Cash From Investing Activities $2.234M $24.37M $10.47M
YoY Change -90.65% 132.74% -107.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 242.0K 0.000 0.000
YoY Change -35.47% -100.0%
NET CHANGE
Cash From Operating Activities -18.47M -31.81M -25.80M
Cash From Investing Activities 2.234M 24.37M 10.47M
Cash From Financing Activities 242.0K 0.000 0.000
Net Change In Cash -16.00M -7.440M -15.33M
YoY Change 927.55% -51.46% -133.81%
FREE CASH FLOW
Cash From Operating Activities -$18.47M -$31.81M -$25.80M
Capital Expenditures $185.0K -$824.0K -$5.719M
Free Cash Flow -$18.66M -$30.98M -$20.08M
YoY Change -13.06% 54.33% -14.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001501756
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36579
dei Entity Registrant Name
EntityRegistrantName
Adverum Biotechnologies, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-5258327
dei Entity Address Address Line1
EntityAddressAddressLine1
100 Cardinal Way
dei Entity Address City Or Town
EntityAddressCityOrTown
Redwood City
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94063
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
656-9323
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
dei Trading Symbol
TradingSymbol
ADVM
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
99729025 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84430000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34195000 usd
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
118834000 usd
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
270993000 usd
CY2022Q3 us-gaap Incentive To Lessee
IncentiveToLessee
0 usd
CY2021Q4 us-gaap Incentive To Lessee
IncentiveToLessee
5709000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9979000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6248000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
213243000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
317145000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
79882000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
86000000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
36579000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33060000 usd
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2503000 usd
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2503000 usd
CY2022Q3 us-gaap Deferred Rent Receivables Net
DeferredRentReceivablesNet
0 usd
CY2021Q4 us-gaap Deferred Rent Receivables Net
DeferredRentReceivablesNet
769000 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
155000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
250000 usd
CY2022Q3 us-gaap Assets
Assets
332362000 usd
CY2021Q4 us-gaap Assets
Assets
439727000 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
846000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1387000 usd
CY2022Q3 advm Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
16539000 usd
CY2021Q4 advm Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
18047000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11236000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1886000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
28621000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21320000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
94464000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
101108000 usd
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
940000 usd
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1114000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
124025000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
123542000 usd
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
10000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
10000 usd
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
980156000 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
964965000 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1953000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-714000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-769876000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-648076000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
208337000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
316185000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
332362000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
439727000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7500000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23849000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24069000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
77078000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
66657000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17188000 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14453000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
46117000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
52546000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
41037000 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
38522000 usd
us-gaap Operating Expenses
OperatingExpenses
123195000 usd
us-gaap Operating Expenses
OperatingExpenses
119203000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-41037000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-38522000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-123195000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-111703000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
923000 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
160000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1450000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
572000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-40114000 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38362000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-121745000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-111131000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
17000 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
55000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-40131000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-38362000 usd
us-gaap Net Income Loss
NetIncomeLoss
-121800000 usd
us-gaap Net Income Loss
NetIncomeLoss
-111131000 usd
CY2022Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-127000 usd
CY2021Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-55000 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-1189000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-50000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-123000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40288000 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-139000 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-30000 usd
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-51000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38468000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-123039000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-111393000 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.13
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
99475000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
99475000 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
98126000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
98126000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
99027000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
99027000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
97966000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
97966000 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
316185000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5381000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000 usd
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
14000 usd
CY2022Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-723000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-37908000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
282952000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4942000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
362000 usd
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-34000 usd
CY2022Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-339000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-43761000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
244122000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4503000 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-30000 usd
CY2022Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-127000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-40131000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
208337000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
434347000 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7224000 usd
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
5000 usd
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1689000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
51000 usd
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-33000 usd
CY2021Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-22000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-28436000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
414820000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8234000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
4000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
526000 usd
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-39000 usd
CY2021Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-62000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-44333000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
379142000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5326000 usd
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-51000 usd
CY2021Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-55000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-38362000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
346000000 usd
us-gaap Net Income Loss
NetIncomeLoss
-121800000 usd
us-gaap Net Income Loss
NetIncomeLoss
-111131000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4816000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3323000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
14826000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
20784000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
277000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-2273000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-101000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
2011000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
1072000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
1526000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
132000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3468000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3493000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-864000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
109000 usd
advm Increase Decrease Operating Lease Right Of Use Asset
IncreaseDecreaseOperatingLeaseRightOfUseAsset
-3092000 usd
advm Increase Decrease Operating Lease Right Of Use Asset
IncreaseDecreaseOperatingLeaseRightOfUseAsset
-2825000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-543000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-587000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-272000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3253000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
55000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0 usd
advm Increase Decrease In Lease Liabilities And Lease Incentive Receivable
IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable
12505000 usd
advm Increase Decrease In Lease Liabilities And Lease Incentive Receivable
IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable
-94000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-89616000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-82016000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
81782000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
328275000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
232899000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
384882000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
8990000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11631000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10771000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
139486000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
54826000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1685000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
51000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
362000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
526000 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
0 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
240000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
365000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2022000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
50235000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-25168000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36698000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
63423000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86933000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38255000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84430000 usd
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32971000 usd
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2503000 usd
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5284000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86933000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38255000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
84005000 usd
advm Remeasurement Of Operating Lease Right Of Use Assets
RemeasurementOfOperatingLeaseRightOfUseAssets
2842000 usd
advm Remeasurement Of Operating Lease Right Of Use Assets
RemeasurementOfOperatingLeaseRightOfUseAssets
0 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
168000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2675000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-769900000 usd
CY2022Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
203300000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the condensed consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, impairment of long-lived assets, income taxes, and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div>
CY2022Q3 advm Cash And Cash Equivalent Amortized Cost
CashAndCashEquivalentAmortizedCost
72987000 usd
CY2022Q3 advm Cash And Cash Equivalent Gross Unrealized Gain
CashAndCashEquivalentGrossUnrealizedGain
2000 usd
CY2022Q3 advm Cash And Cash Equivalent Gross Unrealized Loss
CashAndCashEquivalentGrossUnrealizedLoss
6000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
72983000 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
120336000 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1502000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
118834000 usd
CY2021Q4 advm Cash And Cash Equivalent Amortized Cost
CashAndCashEquivalentAmortizedCost
25808000 usd
CY2021Q4 advm Cash And Cash Equivalent Gross Unrealized Gain
CashAndCashEquivalentGrossUnrealizedGain
0 usd
CY2021Q4 advm Cash And Cash Equivalent Gross Unrealized Loss
CashAndCashEquivalentGrossUnrealizedLoss
1000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
25807000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
271309000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
317000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
270993000 usd
CY2022Q3 advm Debt Securities Available For Sale Maturity Allocated And Single Maturity Date After One Through Two Years
DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears
9600000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
167900000 usd
CY2022Q3 advm Other Than Temporary Impaired Investments Available For Sale Securities
OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities
0 usd
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
53973000 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
46234000 usd
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
17394000 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13174000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
36579000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33060000 usd
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
2000000 usd
CY2022Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
8604000 usd
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
9209000 usd
CY2022Q3 advm Accrued Nonclinical Clinical And Development Process Costs
AccruedNonclinicalClinicalAndDevelopmentProcessCosts
6580000 usd
CY2021Q4 advm Accrued Nonclinical Clinical And Development Process Costs
AccruedNonclinicalClinicalAndDevelopmentProcessCosts
4953000 usd
CY2022Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
301000 usd
CY2021Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
1318000 usd
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
469000 usd
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
550000 usd
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
585000 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2017000 usd
CY2022Q3 advm Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
16539000 usd
CY2021Q4 advm Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
18047000 usd
CY2021Q4 us-gaap Deferred Rent Receivables Net
DeferredRentReceivablesNet
800000 usd
CY2022Q3 us-gaap Deferred Rent Receivables Net
DeferredRentReceivablesNet
0 usd
CY2022Q3 us-gaap Sublease Income
SubleaseIncome
-4100000 usd
us-gaap Sublease Income
SubleaseIncome
-800000 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13288000 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.34
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
10592000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.26
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
15000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.19
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
4644000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.42
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
19221000 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.84
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5302000 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.71
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4503000 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5326000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14826000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20784000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21705000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16852000 shares
CY2022Q3 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Inception To Date
RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate
75 employee
CY2022Q3 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Inception To Date Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent
0.37
CY2021Q4 us-gaap Restructuring Reserve
RestructuringReserve
0 usd
us-gaap Restructuring Charges
RestructuringCharges
4685000 usd
us-gaap Payments For Restructuring
PaymentsForRestructuring
4539000 usd
us-gaap Restructuring Reserve Settled Without Cash2
RestructuringReserveSettledWithoutCash2
53000 usd
CY2022Q3 us-gaap Restructuring Reserve
RestructuringReserve
93000 usd
us-gaap Restructuring Charges
RestructuringCharges
4700000 usd
CY2022Q3 us-gaap Payments For Restructuring
PaymentsForRestructuring
4500000 usd

Files In Submission

Name View Source Status
0001628280-22-029499-index-headers.html Edgar Link pending
0001628280-22-029499-index.html Edgar Link pending
0001628280-22-029499.txt Edgar Link pending
0001628280-22-029499-xbrl.zip Edgar Link pending
advm-20220930.htm Edgar Link pending
advm-20220930.xsd Edgar Link pending
advm-20220930ex311.htm Edgar Link pending
advm-20220930ex312.htm Edgar Link pending
advm-20220930ex321.htm Edgar Link pending
advm-20220930ex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
advm-20220930_htm.xml Edgar Link completed
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
advm-20220930_cal.xml Edgar Link unprocessable
advm-20220930_def.xml Edgar Link unprocessable
advm-20220930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
advm-20220930_pre.xml Edgar Link unprocessable